Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Subodh Verma: Tirzepatide Improves Multiple Cardiovascular Risk Pathways
Subodh Verma/X
Aug 18, 2026, 19:40

Subodh Verma: Tirzepatide Improves Multiple Cardiovascular Risk Pathways

Subodh Verma, Heart Surgeon-Scientist at Unity Health Toronto, Professor and Canada Research Chair, CV Surgery at Temerty Medicine, shared a post on X about a recent article he and his colleagues co-authored, published in JACC, adding:

“Delighted to share this new JACC analysis from SURMOUNT-1.

Over 72 weeks, we saw improvements across multiple pathways linked to cardiovascular risk – including inflammation, insulin resistance, adiposity and hepatic stress, endothelial dysfunction, and thrombosis.

At the 15-mg dose of Tirzepatide, placebo-adjusted changes included a 55% reduction in hsCRP, 30% reduction in IL-6, 39% reduction in HOMA-IR, 61% reduction in leptin, and 44% reduction in PAI-1, with adiponectin increasing by 48%.”

Title: Comprehensive Long-Term Changes in Cardiovascular Risk Biomarkers With Tirzepatide: A SURMOUNT-1 Post Hoc Analysis

Authors: Naveed Sattar, Bruno Linetzky, Giacomo Ruotolo, Subodh Verma, Harald Sourij, Hui Wang, Kadie Vanderman, Jonathan M. Wilson, Ryan M. Griffin, Adam Stefanski, Paul M. Ridker

Subodh Verma

Stay updated on all scientific advnaces with Hemostasis Today.

Adam Stefanski adiponectin adiposity Blood Bruno Linetzky cardiovascular risk Endothelial Dysfunction Giacomo Ruotolo Harald Sourij Health Hematology Hemostasis Hemostasis News Hemostasis Today Hui Wang IL-6 insulin insulin resistance JACC Jonathan M. Wilson Kadie Vanderman leptin Medicine Naveed Sattar Paul M Ridker Ryan M. Griffin Subodh Verma thrombosis Tirzepatide
NewsFeed